Article
Surgery
Carlos Solano, Lourdes Vazquez, Estela Gimenez, Rafael de la Camara, Eliseo Albert, Montserrat Rovira, Ildefonso Espigado, Carmen M. Calvo, Javier Lopez-Jimenez, Maria Suarez-Lledo, Anabella Chinea, Albert Esquirol, Ariadna Perez, Aranzazu Bermudez, Raquel Saldana, Inmaculada Heras, Ana J. Gonzalez-Huerta, Tamara Torrado, Guiomar Bautista, Montserrat Batlle, Santiago Jimenez, Carlos Vallejo, Pere Barba, Maria a. Cuesta, Jose L. Pinana, David Navarro
Summary: The study found that CMV DNAemia was not associated with increased overall mortality and nonrelapse mortality in recipients of allogeneic hematopoietic stem cell transplantation. The use of preemptive antiviral therapy for CMV DNAemia was found to be associated with increased mortality in univariate models, but not in adjusted models. Further research is needed to confirm the potential impact of preemptive antiviral therapy on mortality.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Surgery
Matteo Mombelli, Brian M. Lang, Dionysios Neofytos, John-David Aubert, Christian Benden, Christoph Berger, Katia Boggian, Adrian Egli, Paola M. Soccal, Laurent Kaiser, Cedric Hirzel, Manuel Pascual, Michael Koller, Nicolas J. Mueller, Christian van Delden, Hans H. Hirsch, Oriol Manuel
Summary: The study described the epidemiology and outcomes of respiratory viral infection (RVI) in solid organ transplant (SOT) recipients in Switzerland. The research found that RVI caused important morbidity and may affect long-term outcomes, highlighting the need for improved preventive strategies.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Surgery
Margaret R. Jorgenson, Hanna L. Kleiboeker, Brad C. Astor, Amy C. Gentry, Christopher M. Saddler, Jeannina A. Smith, Fahad Aziz, Didier Mandelbrot, Neetika Garg
Summary: This study evaluated the seasonal distribution of CMV disease in kidney transplant recipients and found that CMV disease is less common during the summer season for patients who were CMV positive at the time of transplantation. However, there was no seasonal variation in CMV disease for CMV negative recipients.
CLINICAL TRANSPLANTATION
(2023)
Article
Medicine, Research & Experimental
Yusuke Isshiki, Motohiko Oshima, Naoya Mimura, Kensuke Kayamori, Yurie Miyamoto-Nagai, Masahide Seki, Yaeko Nakajima-Takagi, Takashi Kanamori, Eisuke Iwamoto, Tomoya Muto, Shokichi Tsukamoto, Yusuke Takeda, Chikako Ohwada, Sonoko Misawa, Jun-Ichiro Ikeda, Masashi Sanada, Satoshi Kuwabara, Yutaka Suzuki, Emiko Sakaida, Chiaki Nakaseko, Atsushi Iwama
Summary: POEMS syndrome is a rare monoclonal plasma cell disorder with unique features and unclear pathogenesis, but the recent study has provided new insights into the disease.
Article
Infectious Diseases
Yuka Torii, Ichiro Morioka, Yasumasa Kakei, Kazumichi Fujioka, Yu Kakimoto, Naoto Takahashi, Tetsushi Yoshikawa, Hiroyuki Moriuchi, Akira Oka, Yoshinori Ito
Summary: This study aimed to compare the accuracy of quantification methods for cytomegalovirus (CMV) infection using whole blood and plasma, and explored the relationship between CMV DNA levels and VGCV therapy. The results showed that plasma CMV viral loads were significantly decreased at the end of therapy, and overall, using plasma to measure CMV viral loads is a feasible approach to monitor the efficacy of CMV infection in children.
BMC INFECTIOUS DISEASES
(2023)
Article
Oncology
Yanjie Xu, Xia Mao, Yimei Que, Menglei Xu, Chunhui Li, Varlene Daniela Fernandes Almeida, Di Wang, Chunrui Li
Summary: This study evaluated the expression of B cell maturation antigen (BCMA) in multiple myeloma (MM) and other plasma cell dyscrasias (PCDs), and aimed to provide a potential treatment strategy for relapsed/refractory PCDs besides MM.
Article
Immunology
Alicja Sadowska-Klasa, Wendy M. Leisenring, Ajit P. Limaye, Michael Boeckh
Summary: A systematic review of randomized and observational studies from 2013-2023 indicated that antiviral preemptive therapy initiated at cytomegalovirus viral load thresholds between 2 and 3 log10 IU/mL had comparable cytomegalovirus disease rates. Thus, viral thresholds within this range appeared to effectively safeguard patients who did not receive prophylaxis.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Virology
K. Yeon Choi, Alistair McGregor
Summary: Research on guinea pig cytomegalovirus (GPCMV) has shown that antibodies to viral glycoprotein complexes, especially the pentamer complex, play a crucial role in protection against congenital cytomegalovirus infection.
Article
Cell Biology
Chang-Ung Kim, Dahwan Lim, Young Sang Kim, Bonsu Ku, Doo-Jin Kim
Summary: Influenza virus Matrix 1 (M1) protein released from virus-infected cells triggers apoptotic cell death in lung epithelial and pulmonary immune cells through Toll-like receptor 4 (TLR4) signaling pathway. This study demonstrates that M1 protein is an important pathogenic factor that enhances influenza virus pathogenicity by promoting cell death in the lungs.
CELL DEATH & DISEASE
(2023)
Article
Surgery
Nathalie Chavarot, Gillian Divard, Anne Scemla, Lucile Amrouche, Olivier Aubert, Marianne Leruez-Ville, Marc O. Timsit, Claire Tinel, Julien Zuber, Christophe Legendre, Dany Anglicheau, Rebecca Sberro-Soussan
Summary: This study analyzed the characteristics and risk factors of CMV disease after conversion to Belatacept in kidney transplant recipients, finding that older age, D+/R- CMV serostatus, and low eGFR at conversion were independent risk factors. The incidence and cumulative incidence of CMV disease were significantly higher in patients treated with Belatacept compared to the control group.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Microbiology
Claire E. Otero, Richard Barfield, Elizabeth Scheef, Cody S. Nelson, Nicole Rodgers, Hsuan-Yuan Wang, Matilda J. Mostrom, Tabitha D. Manuel, Julian Sass, Kimberli Schmidt, Husam Taher, Courtney Papen, Lesli Sprehe, Savannah Kendall, Angel Davalos, Peter A. Barry, Klaus Fruh, Justin Pollara, Daniel Malouli, Cliburn Chan, Amitinder Kaur, Sallie R. Permar
Summary: The study found that in healthy individuals, maternal plasma virus levels and antibody responses are not associated with cCMV following primary maternal infection. Except for CD4+ cell-depleted dams, there were no significant differences in virus levels and antibody responses between immunocompetent dams with and without AF-positive results in terms of cCMV transmission.
Article
Surgery
Mario Fernandez-Ruiz, Beatriz Olea, Patricia Almendro-Vazquez, Estela Gimenez, Alberto Marcacuzco, Rafael San Juan, Iago Justo, Jorge Calvo-Pulido, Alvaro Garcia-Sesma, Alejandro Manrique, Oscar Caso, Felix Cambra, Paloma Talayero, Francisco Lopez-Medrano, Maria Jose Remigia, Tamara Ruiz-Merlo, Patricia Parra, Estela Paz-Artal, Carlos Jimenez, Carmelo Loinaz, David Navarro, Rocio Laguna-Goya, Jose M. Aguado
Summary: Most liver transplant recipients develop detectable but decreasing SARS-CoV-2-CMI after a median of 3 months from COVID-19, with no significant differences compared to immunocompetent patients. Two recipients failed to mount either T cell-mediated or IgG responses.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Hematology
Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Edward R. Scheffer Cliff
Summary: This article discusses the potential benefits and drawbacks of screening for plasma cell dyscrasias, as well as the implications of using mass spectrometry for diagnosing monoclonal gammopathy of undetermined significance in routine practice.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Valentina Tedeschi, Giorgia Paldino, Martina Kunkl, Marino Paroli, Rosa Sorrentino, Loretta Tuosto, Maria Teresa Fiorillo
Summary: CD8(+) T lymphocytes play a crucial role in immune response, but aging and disease can alter their function and phenotype, impacting vaccine and treatment strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Isabelle Montgomerie, Thomas W. Bird, Olga R. Palmer, Ngarangi C. Mason, Theresa E. Pankhurst, Blair Lawley, Leonor C. Hernandez, Rhodri Harfoot, Astrid Authier-Hall, Danielle E. Anderson, Kerry L. Hilligan, Kaitlin H. Buick, Naasson M. Mbenza, Gerd Mittelstadt, Samara Maxwell, Shubhra Sinha, Joanna Kuang, Kanta Subbarao, Emily J. Parker, Alan Sher, Ian F. Hermans, James E. Ussher, Miguel E. Quinones-Mateu, Davide Comoletti, Lisa M. Connor
Summary: Emerging SARS-CoV-2 variants pose a global threat to human health. A sub-unit vaccine composed of an RBD tandem dimer fused to the NTD of the spike protein has been engineered to overcome the poor immunogenicity of RBD proteins. The inclusion of NTD enhances T cell and anti-RBD response, antibody potency, and cross-reactive neutralization activity against multiple SARS-CoV-2 variants.
Article
Hematology
Mark Gurney, Arwen Stikvoort, Emma Nolan, Lucy Kirkham-McCarthy, Stanislav Khoruzhenko, Rama Shivakumar, Sonja Zweegman, Niels W. C. J. Van de Donk, Tuna Mutis, Eva Szegezdi, Subhashis Sarkar, Michael O'Dwyer
Summary: There is strong biological rationale for combining alloeneic natural killer (NK) cell therapies with a chimeric antigen receptor (CAR) to improve the targeting of acute myeloid leukemia (AML). However, CD38 expression on NK cells and its induction during ex vivo NK cell expansion pose challenges to the development of a CD38 CAR-NK cell therapy. This study successfully used gene editing technology to reduce CD38 expression in expanded NK cells, resulting in reduced fratricide and enhanced targeting of primary AML cells. Additionally, pretreatment of AML cells with all-trans retinoic acid further augmented the cytotoxic potential of CD38 CAR-NK cells. These findings support the investigation of CD38 knockdown - CD38 CAR-NK cells as a promising immunotherapeutic approach for AML treatment.
Review
Oncology
Corien Eeltink, Alaa Embaby, Luca Incrocci, Johannes C. F. Ket, Sarah J. Liptrott, Irma Verdonck-de Leeuw, Sonja Zweegman
Summary: The purpose of this study was to examine the prevalence of various sexual problems among patients treated for hematological malignancies without HCT. The results showed that sexual problems occurred in 18-50% of acute leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma patients. However, the understanding of sexual problems in these patients is limited by the variability in methodology and lack of research on patients using novel therapies.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Public, Environmental & Occupational Health
M. G. Caris, N. A. de Jonge, H. J. Punt, D. M. Salet, V. M. T. de Jong, B. Lissenberg-Witte, S. Zweegman, C. M. J. E. Vandenbroucke-Grauls, M. A. van Agtmael, J. J. W. M. Janssen
Summary: Our study shows that the risk of central line associated bloodstream infections (CLABSI) does not appear to increase with longer indwelling time of peripherally inserted central catheters (PICC) in haematology patients. Routine replacement of PICCs is unlikely to prevent CLABSI in this population.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL
(2022)
Article
Hematology
Sabine Haggenburg, Birgit Lissenberg-Witte, Rob S. van Binnendijk, Gerco den Hartog, Michel S. Bhoekhan, Nienke J. E. Haverkate, Dennis M. de Rooij, Johan van Meerloo, Jacqueline Cloos, Neeltje A. Kootstra, Dorine Wouters, Suzanne S. Weijers, Ester M. M. van Leeuwen, Hetty J. Bontkes, Saida Tonouh-Aajoud, Mirjam H. M. Heemskerk, Rogier W. Sanders, Elianne Roelandse-Koop, Quincy Hofsink, Kazimierz Groen, Lucia Cetinel, Louis Schellekens, Yvonne M. den Hartog, Belle Toussaint, Iris M. J. Kant, Thecla Graas, Emma de Pater, Willem A. Dik, Marije D. Engel, Cheyenne R. N. Pierie, Suzanne R. Janssen, Edith van Dijkman, Meliawati Poniman, Judith A. Burger, Joey H. Bouhuijs, Gaby Smits, Nynke Y. Rots, Sonja Zweegman, Arnon P. Kater, Tom van Meerten, Pim G. N. J. Mutsaers, Jaap A. van Doesum, Annoek E. C. Broers, Marit J. van Gils, Abraham Goorhuis, Caroline E. Rutten, Mette D. Hazenberg, Inger S. Nijhof
Summary: Vaccination guidelines for hematological patients are typically conservative. However, this study shows that most patients, even those with compromised immune systems, can develop sufficient antibody concentrations after receiving the Moderna vaccine. However, certain treatments may affect the vaccine's efficacy.
Article
Hematology
Claire N. Harrison, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Jun Zhang, Oumar Sy, Ruben A. Mesa
Summary: This study evaluated the efficacy and safety of Fedratinib in patients with low baseline platelet counts. The results indicated that Fedratinib 400 mg/day is safe and effective for patients with low platelet counts, and no initial dose adjustment is required.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Letter
Hematology
Cathelijne Fokkema, Phillipe Moreau, Bronno van der Holt, Jerome Lambert, Mark van Duin, Ruth Wester, Joost L. M. Jongen, Pieter A. van Doorn, Sophie Godet, KonSiong Jie, Olivier Fitoussi, Michel Delforge, Awa Keita-Manta, Odile Luycx, Tom Cupedo, Niels W. C. J. van de Donk, Sonja Zweegman, Jessica T. Vermeulen, Pieter Sonneveld, Annemiek Broijl
Article
Oncology
Mattia D'Agostino, David A. Cairns, Juan Jose Lahuerta, Ruth Wester, Uta Bertsch, Anders Waage, Elena Zamagni, Maria-Victoria Mateos, Daniele Dall'Olio, Niels W. C. J. van de Donk, Graham Jackson, Serena Rocchi, Hans Salwender, Joan Blade Creixenti, Bronno van der Holt, Gastone Castellani, Francesca Bonello, Andrea Capra, Elias K. Mai, Jan Durig, Francesca Gay, Sonja Zweegman, Michele Cavo, Martin F. Kaiser, Hartmut Goldschmidt, Jesus Maria Hernandez Rivas, Alessandra Larocca, Gordon Cook, Jesus F. San-Miguel, Mario Boccadoro, Pieter Sonneveld
Summary: In this study, the Revised International Staging system (R-ISS) for intermediate-risk multiple myeloma patients was revised based on the additive value of each single risk feature.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Kristine Misund, Davine Hofste Op Bruinink, Eivind Coward, Remco M. Hoogenboezem, Even Holth Rustad, Mathijs A. Sanders, Morten Rye, Anne-Marit Sponaas, Bronno van der Holt, Sonja Zweegman, Eivind Hovig, Leonardo A. Meza-Zepeda, Anders Sundan, Ola Myklebost, Pieter Sonneveld, Anders Waage
Summary: We investigated the genomic and transcriptomic changes in multiple myeloma patients before and after treatment. The study discovered changes in clonal composition and increased single-nucleotide variants. It also found alterations in specific genes and pathways, such as RAS genes, amp1q21, and TP53, and identified increased expression of potentially targetable genes in late-stage disease.
Article
Oncology
Maria-Victoria Mateos, Katja Weisel, Valerio De Stefano, Hartmut Goldschmidt, Michel Delforge, Mohamad Mohty, Michele Cavo, Ravi Vij, Joanne Lindsey-Hill, Dominik Dytfeld, Emanuele Angelucci, Aurore Perrot, Reuben Benjamin, Niels W. C. J. van de Donk, Enrique M. Ocio, Christof Scheid, Francesca Gay, Wilfried Roeloffzen, Paula Rodriguez-Otero, Annemiek Broijl, Anna Potamianou, Caline Sakabedoyan, Maria Semerjian, Sofia Keim, Vadim Strulev, Jordan M. Schecter, Martin Vogel, Robert Wapenaar, Tonia Nesheiwat, Jesus San-Miguel, Pieter Sonneveld, Hermann Einsele, Philippe Moreau
Summary: This is the first prospective study for relapsed/refractory multiple myeloma patients, showing a lack of clear standard of care in real-world practice for heavily pretreated patients and resulting in poor outcomes. This supports the need for new treatments with novel mechanisms of action.
Article
Oncology
Adam D. Cohen, Samir Parekh, Bianca D. Santomasso, Jaime Gallego Perez-Larraya, Niels W. C. J. van de Donk, Bertrand Arnulf, Maria-Victoria Mateos, Nikoletta Lendvai, Carolyn C. Jackson, Kevin C. De Braganca, Jordan M. Schecter, Loreta Marquez, Erin Lee, Ingrid Cornax, Enrique Zudaire, Claire Li, Yunsi Olyslager, Deepu Madduri, Helen Varsos, Lida Pacaud, Muhammad Akram, Dong Geng, Andrzej Jakubowiak, Hermann Einsele, Sundar Jagannath
Summary: This study assessed the associated factors for movement and neurocognitive treatment-emergent adverse events (MNTs) in patients with multiple myeloma treated with cilta-cel. Strategies were implemented to monitor and manage patients with MNTs, leading to a significant reduction in the incidence of adverse events.
BLOOD CANCER JOURNAL
(2022)
Letter
Oncology
Mirian Brink, Monique C. Minnema, Otto Visser, Mark-David Levin, Eduardus F. M. Ward Posthuma, Annemiek Broijl, Pieter Sonneveld, Marjolein van der Klift, Wilfried W. H. Roeloffzen, Matthijs Westerman, Cleo R. van Rooijen, Paul A. F. Geerts, Sonja Zweegman, Niels W. C. J. van de Donk, Avinash G. Dinmohamed
BLOOD CANCER JOURNAL
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Stefanie Slot, Cristina Lavini, Gerben J. C. Zwezerijnen, Bouke J. H. Boden, J. Tim Marcus, Marc C. Huisman, Maqsood Yaqub, Ellis Barbe, Marielle J. Wondergem, Josee M. Zijlstra, Sonja Zweegman, Pieter G. Raijmakers
Summary: The current diagnostic criteria for myelofibrosis are limited by sampling errors in bone marrow (BM) biopsies. Explorative studies have suggested imaging as an alternative for evaluating disease activity, but the choice of optimal technique is complicated due to heterogeneity in BM abnormalities. This prospective diagnostic pilot study used PET/CT and MRI to visualize all BM abnormalities in myelofibrosis before and during ruxolitinib treatment.
